|Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …|
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
|Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer|
E Razis, M Bobos, V Kotoula, AG Eleftheraki, HP Kalofonos, K Pavlakis, ...
Breast cancer research and treatment 128 (2), 447-456, 2011
|Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer|
KS Purrington, S Slager, D Eccles, D Yannoukakos, PA Fasching, P Miron, ...
Carcinogenesis 35 (5), 1012-1019, 2014
|Antitumor Effects of the Proteasome Inhibitor Bortezomib in Medullary and Anaplastic Thyroid Carcinoma Cells in Vitro|
CS Mitsiades, D McMillin, V Kotoula, V Poulaki, C McMullan, J Negri, ...
The Journal of Clinical Endocrinology & Metabolism 91 (10), 4013-4021, 2006
|Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto’s thyroiditis|
N Mitsiades, V Poulaki, V Kotoula, G Mastorakos, S Tseleni-Balafouta, ...
The Journal of Clinical Endocrinology & Metabolism 83 (6), 2199-2203, 1998
|Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma|
M Vassilakopoulou, M Avgeris, V Velcheti, V Kotoula, T Rampias, ...
Clinical Cancer Research 22 (3), 704-713, 2016
|Regulation of vascular endothelial growth factor expression by insulin-like growth factor I in thyroid carcinomas|
V Poulaki, CS Mitsiades, C McMullan, D Sykoutri, G Fanourakis, ...
The Journal of Clinical Endocrinology & Metabolism 88 (11), 5392-5398, 2003
|Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes|
G Pentheroudakis, V Kotoula, W De Roock, G Kouvatseas, P Papakostas, ...
BMC cancer 13 (1), 1-12, 2013
|Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase|
N Mitsiades, V Poulaki, V Kotoula, A Leone, M Tsokos
The American journal of pathology 153 (6), 1947-1956, 1998
|Regulation of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in thyroid carcinoma cells|
V Poulaki, CS Mitsiades, V Kotoula, S Tseleni-Balafouta, A Ashkenazi, ...
The American journal of pathology 161 (2), 643-654, 2002
|Targeted KRAS mutation assessment on patient tumor histologic material in real time diagnostics|
V Kotoula, E Charalambous, B Biesmans, A Malousi, E Vrettou, ...
PloS one 4 (11), e7746, 2009
|Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion|
N Mitsiades, V Poulaki, G Mastorakos, S Tseleni-Balafouta, V Kotoula, ...
The Journal of Clinical Endocrinology & Metabolism 84 (8), 2924-2932, 1999
|Volumetric and MGMT parameters in glioblastoma patients: survival analysis|
G Iliadis, V Kotoula, A Chatzisotiriou, D Televantou, AG Eleftheraki, ...
BMC cancer 12 (1), 1-13, 2012
|Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib|
MG Ooi, PJ Hayden, V Kotoula, DW McMillin, E Charalambous, ...
Clinical Cancer Research 15 (23), 7153-7160, 2009
|Revisiting OCT4 expression in peripheral blood mononuclear cells|
V Kotoula, SI Papamichos, AF Lambropoulos
Stem Cells 26 (1), 290-291, 2008
|Differential response of immunohistochemically defined breast cancer subtypes to anthracycline-based adjuvant chemotherapy with or without paclitaxel|
G Fountzilas, U Dafni, M Bobos, A Batistatou, V Kotoula, H Trihia, ...
PloS one 7 (6), e37946, 2012
|Epidermal growth factor receptor as a therapeutic target in human thyroid carcinoma: mutational and functional analysis|
CS Mitsiades, V Kotoula, V Poulaki, E Sozopoulos, J Negri, ...
The Journal of Clinical Endocrinology & Metabolism 91 (9), 3662-3666, 2006
|Telomerase activity in precancerous hepatic nodules|
P Hytiroglou, V Kotoula, SN Thung, M Tsokos, MI Fiel, CS Papadimitriou
Cancer: Interdisciplinary International Journal of the American Cancer …, 1998
|Tumor PIK3CA genotype and prognosis in early-stage breast cancer: a pooled analysis of individual patient data|
D Zardavas, L Te Marvelde, RL Milne, D Fumagalli, G Fountzilas, ...
Journal of Clinical Oncology 36 (10), 981-+, 2018
|Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin …|
D Pectasides, V Karavasilis, G Papaxoinis, G Gourgioti, T Makatsoris, ...
BMC cancer 15 (1), 1-11, 2015